Duchenne muscular dystrophy.
neuromuscular disease characterized by rapidly progressive muscle weakness and wasting due to degeneration of skeletal, smooth and cardiac muscle
Capricor investor lawsuit deadline nears amid claims of hidden FDA changes
Multiple firms have filed or announced securities class actions against Capricor Therapeutics over allegations that the company changed its statistical analysis plan for its Duchenne drug Deramiocel without FDA agreement, contributing to a 64% stock drop after July 27 briefing documents were released; lead plaintiff deadlines are set for September 28, 2026. The lawsuits allege false and misleading statements and highlight ongoing regulatory scrutiny as the FDA extended review timelines, with firms urging affected investors to seek appointment as lead plaintiffs.
Finance · 6 sources · Sep 2, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy predominantly affecting males. The onset of muscle weakness typically begins around age four, with rapid progression. Initially, muscle loss occurs in the thighs and pelvis, extending to the arms, which can lead to difficulties in standing up. By the age of 12, most individuals with Duchenne muscular dystrophy are unable to walk. Affected muscles may appear larger due to an increase in fat content, and scoliosis is common. Some individuals may experience intellectual disability, and females carrying a single copy of the mutated gene may show mild symptoms.
Everything about Duchenne muscular dystrophy →